Abstract:Context: Germline testing (GT) is increasingly impacting prostate cancer (PCa) management and screening, with direct effects in urology, medical oncology, and radiation oncology. The majority of testing indications and recommendations center on men with metastatic disease, although guidelines now encompass newly diagnosed, early-stage PCa and entail assessment of personal history, pathologic features, and family history to determine eligibility for testing. Objective: To describe current guidelines on GT for men with PCa and the impact on management. An additional objective was to review the literature on current uptake of GT across practice settings. Evidence acquisition: A nonsystematic review was performed of current guidelines on GT in PCa from professional societies and consensus conferences, detailing supporting evidence for these recommendations. This was supplemented by a literature review of uptake of GT and precision medicine in practice. Evidence synthesis: Multiple guidelines and consensus panels recommend GT for men with metastatic PCa. Guidelines endorse BRCA2 testing in metastatic PCa because of strong evidence for PCa risk, aggressiveness, and PARP inhibitor candidacy. Testing of additional DNA repair genes in metastatic disease is also endorsed across guidelines. Immunotherapy with pembrolizumab is an option in some guidelines for men with DNA mismatch repair deficiency. In localized disease, GT is recommended on the basis of histologic features and family history; criteria vary between guidelines. GT for localized disease informs hereditary cancer risk and will probably impact future PCa management. Practice gaps exist regarding utilization of GT. Conclusions: Germline evaluation is increasingly important in the management of men with metastatic PCa and may also affect the prognosis for men with localized disease. The presence of germline mutations has important hereditary cancer implications for men and their families. Uptake of germline evaluation may be underutilized in some practice settings, so strategies for optimization are required. Patient summary: Patients with prostate cancer should talk to their doctor about the pros and cons of genetic testing, with attention to family history and cancer features. Genetic testing can have important implications for treatment, cancer screening, and family cancer risk.

Prostate cancer and genetic contributions

Genetic testing for hereditary prostate cancer: Current status and limitations

A Genetic Study and Meta-Analysis of the Genetic Predisposition of Prostate Cancer in a Chinese Population

Genetics of prostate cancer: a review of latest evidence

Prostate Cancer: A Review of Genetics, Current Biomarkers and Personalised Treatments

Prostate cancer genotyping for risk stratification and precision treatment

Genetic Factors Underlying Prostate Cancer

Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches

Incorporating Genetic Risk Into Prostate Cancer Care: Implications for Early Detection and Precision Oncology

Germline genetic profiling in prostate cancer: latest developments and potential clinical applications

Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer

Hereditary and Familial Traits in Urological Cancers and Their Underlying Genes

Hereditary gynecologic tumors and precision cancer medicine

Contribution of Inherited DNA-Repair Gene Mutations to Hormone-Sensitive and Castrate-Resistant Metastatic Prostate Cancer and Implications for Clinical Outcome.

Clinical implications of genomic alterations in metastatic prostate cancer

Characterising the contribution of rare protein-coding germline variants to prostate cancer risk and severity in 37,184 cases

Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing

Mechanistic insights into genetic susceptibility to prostate cancer

Inherited Mutations in Chinese Men With Prostate Cancer

Research progress of familial and hereditary prostate cancer

Review on the Role of BRCA Mutations in Genomic Screening and Risk Stratification of Prostate Cancer